Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
06-08 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
06-08 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
30 Jan 2023
// CLINICAL TRIALS ARENA
https://www.clinicaltrialsarena.com/news/ammax-bio-subjects-trial-tgct/
30 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/01/30/2597498/0/en/AmMax-Bio-Announces-First-Patients-Dosed-in-Phase-2b-Study-of-AMB-05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT.html
19 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/01/19/2592112/0/en/AmMax-Bio-s-AMB-05X-Receives-EMA-PRIME-Designation-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT.html
09 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/01/09/2585142/0/en/AmMax-Bio-Enters-into-an-Exclusive-Option-Agreement-with-Evopoint-Biosciences-to-License-a-Next-Generation-Antibody-Drug-Conjugate-ADC-for-the-Treatment-of-Solid-Tumors.html
18 Nov 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/11/18/2559064/0/en/AmMax-Bio-Announces-Oral-Presentation-of-Phase-2-Data-of-AMB-05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT-at-the-2022-CTOS-Annual-Meeting.html
26 Sep 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/09/26/2522462/0/en/AmMax-Bio-Provides-Update-on-AMB-05X-Program-for-Tenosynovial-Giant-Cell-Tumor-TGCT.html
ABOUT THIS PAGE